Osimertinib/osimertinib reimbursement policy in 2024

Osimertinib/Osimertinib (Osimertinib) is an oral targeted therapy drug mainly used to treat advanced non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) inhibitor with highly selective and potent inhibitory effects.

The original drug OsimertinibOsimertinib/Osimertinib, which has been marketed in China, has now been included in the scope of medical insurance, and domestic patients can easily purchase it. The price is roughly around three to four thousand yuan, but for specific prices and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy to obtain the most accurate information. On the other hand, there are some more affordable generic drugs on the foreign market, mainly Laos version and Bangladesh version generic drugs. The selling prices of these generic drugs are basically around a few hundred yuan, which has obvious advantages compared with domestic prices. It is worth mentioning that the ingredients of these generic drugs are highly consistent with the original drugs.

Reimbursement is limited only to: 1. Stage IB-IIIA non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation For the treatment of patients with (NSCLC), the patient must have previously undergone surgical resection, and the doctor must decide whether to accept adjuvant chemotherapy;

2． Long-line therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon19 deletion or exon21 (L858R) substitution mutation;

3． Previous disease progression during or after treatment with EGFRtyrosine kinase inhibitors (TKI), and the presence of EGFR T790M has been confirmed by testingTreatment of adult patients with mutation-positive locally advanced or metastatic NSCLC.

Compared with other EGFR inhibitors, osimertinib/osimertinib has higher selectivity, especially against EGFR mutants, such as T790M mutation. This mutation is one of the common causes of resistance to EGFR inhibitor treatments. Osimertinib/Osimertinib inhibits the activity of this mutated EGFR protein, thereby effectively inhibiting tumor growth.

Clinical trials have shown that osimertinib/osimertinib has shown good efficacy and tolerability in the treatment of NSCLC patients. It is approved for use in patients who have developed resistance to other EGFR inhibitors and in patients with advanced NSCLC who have EGFR mutations, including the T790M mutation.

Osimertinib/OsimertinibOsimertinib is usually used as a first-line treatment option, but it can also be used as an option for subsequent treatment. It is often used in combination with other treatment modalities, such as chemotherapy or immunotherapy, to increase effectiveness.